Issue Date: April 18, 2016
Juno boosts cellular therapy partnerships
Juno Therapeutics will collect $50 million now that Celgene has exercised an option to develop its cellular therapies targeting CD19 outside of North America and China. Juno’s CD19 portfolio includes three drug candidates; one, JCAR015, is in Phase II studies to treat acute lymphoblastic leukemia. Last year, Celgene paid $1 billion for the rights to opt in to Juno’s cellular therapies. Separately, Juno and WuXi AppTec have started JW Biotechnology in China to pair Juno’s cellular therapy technology with WuXi’s R&D and manufacturing expertise.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society